Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Destiny Pharma
Biotech
Destiny ends COVID collab, Santhera returns lonodelestat
Both Destiny and Santhera explained why a tighter clinical focus comes at the expense of one of their potential assets
James Waldron
Apr 25, 2024 8:23am
Destiny seals C. diff therapy's phase 3 fate with Sebela
Feb 24, 2023 10:10am
Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders
May 6, 2022 9:30am
EuroBiotech Report—Cellectis, NuCana, Nightstar, Destiny and Verona
Sep 7, 2017 2:36pm
Destiny pulls off IPO to fund infection-prevention trial
Sep 5, 2017 9:10am
EuroBiotech: More Articles of Note
Aug 24, 2017 9:48am
